Future directions in the treatment of Parkinson's disease
Identifieur interne : 003D58 ( Main/Merge ); précédent : 003D57; suivant : 003D59Future directions in the treatment of Parkinson's disease
Auteurs : Anthony H. V. Schapira [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- Cholinergic Antagonists (therapeutic use), Coenzymes (therapeutic use), Dopamine Agonists (therapeutic use), Drug Therapy (trends), Forecasting, Humans, Intercellular Signaling Peptides and Proteins (therapeutic use), MAOB inhibitors, Monoamine Oxidase Inhibitors (therapeutic use), Parkinson Disease (drug therapy), Parkinson's disease, Ubiquinone (analogs & derivatives), Ubiquinone (therapeutic use), adenosine A2a antagonists., dopamine agonists, neuroprotection.
- MESH :
- chemical , analogs & derivatives : Ubiquinone.
- chemical , therapeutic use : Cholinergic Antagonists, Coenzymes, Dopamine Agonists, Intercellular Signaling Peptides and Proteins, Monoamine Oxidase Inhibitors, Ubiquinone.
- drug therapy : Parkinson Disease.
- trends : Drug Therapy.
- Forecasting, Humans.
Abstract
The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21679
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E65
- to stream Istex, to step Curation: 000E65
- to stream Istex, to step Checkpoint: 001944
- to stream PubMed, to step Corpus: 002341
- to stream PubMed, to step Curation: 002341
- to stream PubMed, to step Checkpoint: 002808
- to stream Ncbi, to step Merge: 002018
- to stream Ncbi, to step Curation: 002018
- to stream Ncbi, to step Checkpoint: 002018
Links to Exploration step
ISTEX:17DC5AE4B28D6BD4538FACE203DB294ECCA42140Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Future directions in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:17DC5AE4B28D6BD4538FACE203DB294ECCA42140</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21679</idno><idno type="url">https://api.istex.fr/document/17DC5AE4B28D6BD4538FACE203DB294ECCA42140/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E65</idno><idno type="wicri:Area/Istex/Curation">000E65</idno><idno type="wicri:Area/Istex/Checkpoint">001944</idno><idno type="wicri:doubleKey">0885-3185:2007:Schapira A:future:directions:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18175401</idno><idno type="wicri:Area/PubMed/Corpus">002341</idno><idno type="wicri:Area/PubMed/Curation">002341</idno><idno type="wicri:Area/PubMed/Checkpoint">002808</idno><idno type="wicri:Area/Ncbi/Merge">002018</idno><idno type="wicri:Area/Ncbi/Curation">002018</idno><idno type="wicri:Area/Ncbi/Checkpoint">002018</idno><idno type="wicri:doubleKey">0885-3185:2007:Schapira A:future:directions:in</idno><idno type="wicri:Area/Main/Merge">003D58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Future directions in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007">2007</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">S17</biblScope><biblScope unit="supplement">S17</biblScope><biblScope unit="page" from="S385">S385</biblScope><biblScope unit="page" to="S391">S391</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">17DC5AE4B28D6BD4538FACE203DB294ECCA42140</idno><idno type="DOI">10.1002/mds.21679</idno><idno type="ArticleID">MDS21679</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cholinergic Antagonists (therapeutic use)</term><term>Coenzymes (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Therapy (trends)</term><term>Forecasting</term><term>Humans</term><term>Intercellular Signaling Peptides and Proteins (therapeutic use)</term><term>MAOB inhibitors</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Ubiquinone (analogs & derivatives)</term><term>Ubiquinone (therapeutic use)</term><term>adenosine A2a antagonists.</term><term>dopamine agonists</term><term>neuroprotection</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cholinergic Antagonists</term><term>Coenzymes</term><term>Dopamine Agonists</term><term>Intercellular Signaling Peptides and Proteins</term><term>Monoamine Oxidase Inhibitors</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Forecasting</term><term>Humans</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.21679"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Future directions in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:17DC5AE4B28D6BD4538FACE203DB294ECCA42140</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21679</idno><idno type="url">https://api.istex.fr/document/17DC5AE4B28D6BD4538FACE203DB294ECCA42140/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E65</idno><idno type="wicri:Area/Istex/Curation">000E65</idno><idno type="wicri:Area/Istex/Checkpoint">001944</idno><idno type="wicri:doubleKey">0885-3185:2007:Schapira A:future:directions:in</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Future directions in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007">2007</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">S17</biblScope><biblScope unit="supplement">S17</biblScope><biblScope unit="page" from="S385">S385</biblScope><biblScope unit="page" to="S391">S391</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">17DC5AE4B28D6BD4538FACE203DB294ECCA42140</idno><idno type="DOI">10.1002/mds.21679</idno><idno type="ArticleID">MDS21679</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MAOB inhibitors</term><term>Parkinson's disease</term><term>adenosine A2a antagonists.</term><term>dopamine agonists</term><term>neuroprotection</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Future directions in the treatment of Parkinson's disease.</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name><affiliation wicri:level="3"><nlm:affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, UK. a.schapira@medsch.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:18175401</idno><idno type="pmid">18175401</idno><idno type="doi">10.1002/mds.21679</idno><idno type="wicri:Area/PubMed/Corpus">002341</idno><idno type="wicri:Area/PubMed/Curation">002341</idno><idno type="wicri:Area/PubMed/Checkpoint">002808</idno><idno type="wicri:Area/Ncbi/Merge">002018</idno><idno type="wicri:Area/Ncbi/Curation">002018</idno><idno type="wicri:Area/Ncbi/Checkpoint">002018</idno><idno type="wicri:doubleKey">0885-3185:2007:Schapira A:future:directions:in</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Future directions in the treatment of Parkinson's disease.</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name><affiliation wicri:level="3"><nlm:affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, UK. a.schapira@medsch.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cholinergic Antagonists (therapeutic use)</term><term>Coenzymes (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Therapy (trends)</term><term>Forecasting</term><term>Humans</term><term>Intercellular Signaling Peptides and Proteins (therapeutic use)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Ubiquinone (analogs & derivatives)</term><term>Ubiquinone (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cholinergic Antagonists</term><term>Coenzymes</term><term>Dopamine Agonists</term><term>Intercellular Signaling Peptides and Proteins</term><term>Monoamine Oxidase Inhibitors</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Forecasting</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2-adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late-stage development for PD and offer benefit for motor symptoms and motor complications.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003D58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:17DC5AE4B28D6BD4538FACE203DB294ECCA42140
|texte= Future directions in the treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |